FOLD News and Press, Amicus Therapeutics Inc. From 07/19/21

Hailshadow/iStock via Getty Images Citing expert opinion on the company’s experimental therapy for Pompe disease, BTIG has assumed a buy rating on Amicus Therapeutics ([[FOLD]] +0.3%). In February, the company failed to meet the primary endpoint in a Phase 3 trial for AT-GAA (cipagluco...

Using the quarterly 13F filings we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holding...

Amicus produced mixed results in the PROPEL trial. However, it has a high chance of approval on data from this and earlier trials. Its Galafold franchise is progressing strongly. For further details see: Amicus Therapeutics: The Pompe Data Slump Was An Overreaction

Lone Pine Capital’s 13F portfolio value increased marginally from $27.51B to $27.53B. The number of positions decreased from 41 to 38. They increased Facebook, Microsoft, and DoorDash while dropping DocuSign, Autodesk, and Humana. The top three positions are Shopify, Micros...

PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry...

Amicus Therapeutics (FOLD) announces that the U.K.’s Medicines and Healthcare Products Regulatory Agency ((MHRA)) has granted a positive scientific opinion through the Early Access to Medicines Scheme ((EAMS)) to AT-GAA, the Company’s investigational two-component ther...

Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the UK Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS) Recognizes High Unmet Medical Need in ERT Treated Late-Onset Pompe Disease Pat...

PHILADELPHIA, May 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman Sachs 42 nd Annual Global Healthcare Conference, being held virtually on Wednesday, June...

Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) traded today at $8.79, breaking its 52-week low. Approximately 404,000 shares have changed hands today, as compared to an average 30-day volume of 2.4 million shares. Amicus Therapeutics Inc. has overhead space with shares priced $8.95, or...

Amicus Therapeutics Inc. (NASDAQ:FOLD) traded today at a new 52-week low of $8.72. Approximately 204,000 shares have changed hands today, as compared to an average 30-day volume of 2.4 million shares. In the past 52 weeks, shares of Amicus Therapeutics Inc. have traded between the curren...